Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response

BACKGROUND: Immune checkpoint blockade (ICB) therapies have changed the paradigm of cancer therapies. However, anti-tumor response of the ICB is insufficient for many patients and limited to specific tumor types. Despite many preclinical and clinical studies to understand the mechanism of anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Yosuke, Fu, Yu, Liu, Hong, Lee, Min Young, Shaw, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590766/
https://www.ncbi.nlm.nih.gov/pubmed/34774008
http://dx.doi.org/10.1186/s12885-021-08974-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590766/
https://www.ncbi.nlm.nih.gov/pubmed/34774008
http://dx.doi.org/10.1186/s12885-021-08974-3

Ejemplares similares